SPECIALTY TOPICS · GUIDE
Financial Conflicts in Emerging Health Products
How money can shape research and clinic advice for emerging treatments, what U.S. rules require researchers to disclose, what the Cochrane review found about sponsorship, and how to check.
Content last updated . This page has not been medically reviewed.
Back to Emerging Wellness ScienceThe basic idea
A financial conflict of interest exists when someone who helps decide what is studied, reported or recommended also stands to gain from the answer. It does not prove anyone is wrong or dishonest. It is a reason to look more closely, and to look for independent confirmation. This page is information only. It does not say any named person or organization has a conflict.What U.S. rules define and require
For FDA marketing applications that rely on clinical studies, 21 CFR Part 54 sets out what companies must disclose about the financial interests of the investigators. [1] [2] The definitions are specific:| Term (21 CFR 54.2) | What it covers |
|---|---|
| Compensation affected by the outcome | Pay that could be higher for a favorable outcome, such as equity in the sponsor or a royalty tied to sales [1] |
| Significant equity interest | Any ownership interest whose value cannot be readily determined from public prices, or an equity interest in a publicly traded company above $50,000 while the study runs and for 1 year after [1] |
| Proprietary interest | Property or financial interest in the tested product, such as a patent, trademark, copyright or licensing agreement [1] |
| Significant payments of other sorts | Sponsor payments to the investigator or institution above $25,000, apart from the costs of running the study, such as grants, equipment, retainers or honoraria [1] |
Under 54.4, the applicant must submit, for each investigator in a covered study, either a certification that none of these arrangements exist or a disclosure of what they are. [2] "Covered" generally means studies used to establish effectiveness, or where a single investigator contributes significantly to safety. It generally does not include Phase 1 tolerance studies or most clinical pharmacology studies. [1] The rule is framed around companies' marketing applications to the FDA.
For research funded by the U.S. Public Health Service, 42 CFR 50.605 requires an institution to review investigators' significant financial interests and, where a conflict exists, to put a management plan in place. [3] Examples include public disclosure when presenting or publishing, disclosure directly to participants in human-subjects research, an independent monitor, changes in personnel, reducing the financial interest and severing relationships. [3]
Open Payments: a public database in the United States
Open Payments is a national disclosure program run by the Centers for Medicare & Medicaid Services (CMS). It houses a public database of payments and other transfers of value that reporting entities, including drug and medical device companies, make to covered recipients such as physicians, and ownership or investment interests held by physicians or their immediate family. [4] CMS says Program Year 2025 data include 17.07 million published records totaling $14.67 billion. [4] CMS also says it does not comment on what relationships may be beneficial or potential conflicts of interest. [4] The page we read does not describe a clinic's income from selling its own treatments, so a person's absence from the database is not the same as having no financial stake.What the research says about sponsorship
A Cochrane methodology review of 75 papers (updated 2017) compared industry-sponsored drug and device studies with studies sponsored in other ways. [5]- Industry-sponsored studies more often had favorable efficacy results (risk ratio 1.27, 95% CI 1.17 to 1.37, moderate-quality evidence) and more often favorable conclusions (RR 1.34, 95% CI 1.19 to 1.51, low-quality evidence). [5]
- Harms results were similar (RR 1.37, 95% CI 0.64 to 2.93, very low-quality evidence). [5]
- Standard risk-of-bias ratings did not explain the gap. The authors concluded this suggests an industry bias that cannot be explained by standard risk-of-bias assessments. [5]
Evidence label: mixed. This is a review of research methods across human drug and device studies. It describes drug and device studies in general. It does not tell you whether a particular emerging product's studies are biased. See conflicts of interest and funding in research.
Money in the clinic
A clinic that recommends and sells the same product has a direct financial interest in your decision. Nothing about that is automatically wrong. But the FDA says that if you are being charged for regenerative medicine products outside a clinical trial, you are likely being deceived and offered a product illegally. [6] Testimonials, trial registrations and disclaimers do not replace independent evidence. See stem cell and regenerative clinics marketed for aging.Questions to ask
- Who paid for the study, and who wrote the report?
- Do the investigators have patents, equity, royalties or consulting fees related to the product?
- Is the same person doing the research, giving the advice and selling the treatment?
- Is there confirmation from a group with no stake?
Related guides
Overpromising and the limits of disclaimers, how to read health product marketing claims and unapproved commercial interventions.Frequently asked questions
Does a financial conflict mean the research is wrong?
No. It is a reason to check more carefully. The Cochrane review found sponsorship associated with more favorable efficacy results and conclusions on average, not that every sponsored study is wrong. [5]
Must researchers disclose what they earn?
For studies submitted in U.S. FDA marketing applications, the applicant must certify or disclose investigators' financial arrangements. [2] For PHS-funded research, institutions must manage financial conflicts. [3]
Can I look up payments to my doctor?
In the United States, the Open Payments database publishes payments from drug and device companies to covered recipients such as physicians. [4]
Is a clinic's disclaimer enough?
No. See overpromising and the limits of disclaimers. The FDA says registering with the agency or being listed on ClinicalTrials.gov does not mean a product is legally marketed. [6]
References
- U.S. Code of Federal Regulations, Title 21, Section 54.2. Definitions (financial disclosure by clinical investigators). eCFR. Read 2026-10-22.
- U.S. Code of Federal Regulations, Title 21, Section 54.4. Certification and disclosure requirements. eCFR. Read 2026-10-22.
- U.S. Code of Federal Regulations, Title 42, Section 50.605. Management and reporting of financial conflicts of interest. eCFR. Read 2026-10-22.
- Centers for Medicare & Medicaid Services (United States). Open Payments. Page last modified 2026-06-30. Read 2026-10-22.
- Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2017;2:MR000033. Read 2026-10-22.
- U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. Posted June 3, 2021; content current as of 04/08/2024. Read 2026-10-22.